413 related articles for article (PubMed ID: 31821456)
1. Vedolizumab for prevention of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
Chen YB; Shah NN; Renteria AS; Cutler C; Jansson J; Akbari M; Chen C; Quadri S; Parfionovas A; Devine SM
Blood Adv; 2019 Dec; 3(23):4136-4146. PubMed ID: 31821456
[TBL] [Abstract][Full Text] [Related]
2. Safety and Effectiveness of Vedolizumab in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease: A Retrospective Record Review.
Fløisand Y; Lazarevic VL; Maertens J; Mattsson J; Shah NN; Zachée P; Taylor A; Akbari M; Quadri S; Parfionovas A; Chen YB
Biol Blood Marrow Transplant; 2019 Apr; 25(4):720-727. PubMed ID: 30468919
[TBL] [Abstract][Full Text] [Related]
3. Gut Immunomodulation with Vedolizumab prior to Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Patients with Inflammatory Bowel Disease.
Chopra Y; Acevedo K; Muise A; Frost K; Schechter T; Krueger J; Ali M; Chiang KY; Kim VH; Grunebaum E; Wall D
Transplant Cell Ther; 2024 May; 30(5):546.e1-546.e7. PubMed ID: 38458476
[TBL] [Abstract][Full Text] [Related]
4. Vedolizumab in highly resistant acute gastrointestinal graft-versus-host disease after allogeneic stem cell transplantation: A single-center pediatric series.
Rosa M; Jarmoliński T; Miśkiewicz-Migoń I; Liszka K; Miśkiewicz-Bujna J; Panasiuk A; Frączkiewicz J; Ussowicz M
Adv Clin Exp Med; 2022 Mar; 31(3):345-350. PubMed ID: 35212198
[TBL] [Abstract][Full Text] [Related]
5. Intestinal Microbiota Can Predict Acute Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation.
Han L; Zhang H; Chen S; Zhou L; Li Y; Zhao K; Huang F; Fan Z; Xuan L; Zhang X; Dai M; Lin Q; Jiang Z; Peng J; Jin H; Liu Q
Biol Blood Marrow Transplant; 2019 Oct; 25(10):1944-1955. PubMed ID: 31299215
[TBL] [Abstract][Full Text] [Related]
6. Vedolizumab for the prevention of intestinal acute GVHD after allogeneic hematopoietic stem cell transplantation: a randomized phase 3 trial.
Chen YB; Mohty M; Zeiser R; Teshima T; Jamy O; Maertens J; Purtill D; Chen J; Cao H; Rossiter G; Jansson J; Fløisand Y
Nat Med; 2024 Jun; ():. PubMed ID: 38844797
[TBL] [Abstract][Full Text] [Related]
7. Gut microbiota intervention by pre and probiotics can induce regulatory T cells and reduce the risk of severe acute GVHD following allogeneic hematopoietic stem cell transplantation.
Yazdandoust E; Hajifathali A; Roshandel E; Zarif MN; Pourfathollah AA; Parkhideh S; Mehdizadeh M; Amini-Kafiabad S
Transpl Immunol; 2023 Jun; 78():101836. PubMed ID: 37037266
[TBL] [Abstract][Full Text] [Related]
8. Cytotoxicity of Donor Natural Killer Cells to Allo-Reactive T Cells Are Related With Acute Graft-vs.-Host-Disease Following Allogeneic Stem Cell Transplantation.
Sheng L; Mu Q; Wu X; Yang S; Zhu H; Wang J; Lai Y; Wu H; Sun Y; Hu Y; Fu H; Wang Y; Xu K; Sun Y; Zhang Y; Zhang P; Zhou M; Lai B; Xu Z; Gao M; Zhang Y; Ouyang G
Front Immunol; 2020; 11():1534. PubMed ID: 32849519
[No Abstract] [Full Text] [Related]
9. [Analysis of risk factors for the development of acute graft-versus-host disease in 151 cases of allo-hematopoietic stem cell transplantation].
Chen Y; Lu DP; Liu KY; Dong LJ; Ren HY; Huang XJ; Chen H; Liu DH; Jiang Q; Chen YH; Xu LP; Zhang YC; Lu J; Gao ZY
Zhonghua Xue Ye Xue Za Zhi; 2005 Feb; 26(2):74-7. PubMed ID: 15921621
[TBL] [Abstract][Full Text] [Related]
10. Risk Factors for Acute Graft-Versus-Host Disease After Allogeneic Haematopoietic Stem Cell Transplantation: A Single-Center Experience.
Wang F; Cai B; Wang L; Gu Z; Luo L; Wei H; Zhao S; Guan L; Wang X; Wang L; Liu D; Gao C
Ann Transplant; 2017 Feb; 22():58-65. PubMed ID: 28154370
[TBL] [Abstract][Full Text] [Related]
11. [Clinical characteristics of acute graft-versus-host disease confined solely to gastrointestinal tract after allogeneic hematopoietic stem cell transplantation].
Feng R; Liu DH; Xu LP; Chen H; Zhang XH; Han W; Zhao T; Liu KY; Huang XJ
Zhonghua Nei Ke Za Zhi; 2010 Dec; 49(12):1028-31. PubMed ID: 21211361
[TBL] [Abstract][Full Text] [Related]
12. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia.
Liu QF; Fan ZP; Zhang Y; Jiang ZJ; Wang CY; Xu D; Sun J; Xiao Y; Tan H
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1376-85. PubMed ID: 19822296
[TBL] [Abstract][Full Text] [Related]
13. High mortality in hematopoietic stem cell transplant-associated thrombotic microangiopathy with and without concomitant acute graft-versus-host disease.
Kraft S; Bollinger N; Bodenmann B; Heim D; Bucher C; Lengerke C; Kleber M; Tsakiris DA; Passweg J; Tzankov A; Medinger M
Bone Marrow Transplant; 2019 Apr; 54(4):540-548. PubMed ID: 30108323
[TBL] [Abstract][Full Text] [Related]
14. Endothelial microparticles delivering microRNA-155 into T lymphocytes are involved in the initiation of acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.
Zhang R; Wang X; Hong M; Luo T; Zhao M; Shen H; Fang J; Li X; Zang S; Chen P; Nie D; Zheng P; Wu Q; Xia L
Oncotarget; 2017 Apr; 8(14):23360-23375. PubMed ID: 28423578
[TBL] [Abstract][Full Text] [Related]
15. Peritransplantation Red Blood Cell Transfusion Is Associated with Increased Risk of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation.
Hosoba S; Waller EK; Shenvi N; Graiser M; Easley KA; Al-Kadhimi Z; Andoh A; Antun AG; Barclay S; Josephson CD; Koff JL; Khoury HJ; Langston AA; Zimring JC; Roback JD; Giver CR
Biol Blood Marrow Transplant; 2018 May; 24(5):973-982. PubMed ID: 29307717
[TBL] [Abstract][Full Text] [Related]
16. Thrombotic microangiopathy with concomitant GI aGVHD after allogeneic hematopoietic stem cell transplantation: Risk factors and outcome.
Zhang XH; Liu X; Wang QM; He Y; Zhu XL; Zhang JM; Han W; Chen H; Chen YH; Wang FR; Wang JZ; Zhang YY; Mo XD; Chen Y; Wang Y; Fu HX; Chang YJ; Xu LP; Liu KY; Huang XJ
Eur J Haematol; 2018 Feb; 100(2):171-181. PubMed ID: 29114931
[TBL] [Abstract][Full Text] [Related]
17. Impact of cyclosporine-A concentration in T-cell replete haploidentical allogeneic stem cell transplantation.
Yang X; Yang S; Sun A; Qiu H; Tang X; Han Y; Wu D
Clin Transplant; 2018 Apr; 32(4):e13220. PubMed ID: 29493007
[TBL] [Abstract][Full Text] [Related]
18. Study of kidney function impairment after reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation. A single-center experience.
Piñana JL; Valcárcel D; Martino R; Barba P; Moreno E; Sureda A; Vega M; Delgado J; Briones J; Brunet S; Sierra J
Biol Blood Marrow Transplant; 2009 Jan; 15(1):21-9. PubMed ID: 19135939
[TBL] [Abstract][Full Text] [Related]
19. Mortality, length of stay and costs associated with acute graft-versus-host disease during hospitalization for allogeneic hematopoietic stem cell transplantation.
Yu J; Parasuraman S; Shah A; Weisdorf D
Curr Med Res Opin; 2019 Jun; 35(6):983-988. PubMed ID: 30461314
[TBL] [Abstract][Full Text] [Related]
20. [Clinical study on haploid HLA-matched hematopoietic stem cell transplantation for treatment of malignant hematological disease].
Sun AN; Wu DP; Wang Y; Qiu HY; Jin ZM; Miao M; Tang XW; Fu ZZ; Ma X; Han Y; He GS; Chen SN; Xue SL; Zhao Y
Ai Zheng; 2006 Aug; 25(8):1019-22. PubMed ID: 16965686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
